Marcelle Pick explains how GLP-1 agonists like Ozempic and Wegovy work by regulating blood sugar and suppressing appetite. The drugs were developed as weight-loss treatments, but current shortages are affecting diabetics who need them. Most people see them as important, though few expect them to significantly reduce obesity rates.
How do these drugs work? We've talked about that before. They're known as GLP1 agonists pulling double duty by they regulate blood sugar and they also suppress your appetite. And they work incredibly well for diabetics. But Ozempic in particular and WeGovy is the newest one. That's just for obesity. But the information is very important to understand that they really were started as weight loss medications and now we have shortages for even the diabetics. So many people think that these are game changers as they fight obesity and the public's expectations are a little bit more tempered. Only a minority of people believe that they'll make significant dents in America's obesity rates.
